SPAC Flags Going Concern, Material Weakness, and 35% Discount Convertible Notes
DMII is trading near its 52-week low of $9.86 (2.7% above the low).
Summary
Drugs Made In America Acquisition II Corp. reports going concern doubts, a material weakness, and new convertible notes with a 35% discount to market price.
Key Events · Earnings and Guidance · DMII
-
Going Concern Warning Reiterated
Working capital deficit of $426,751 as of June 30, 2026; management states substantial doubt about ability to continue as a going concern within one year.
-
Material Weakness in Internal Controls
Disclosure controls ineffective due to inadequate segregation of duties, insufficient written policies, and lack of formal review for related party transactions.
-
Sponsor Unable to Repay $782,113
Full reserve established against amount due from sponsor after board learned sponsor cannot repay; only $30,000 recovered during the quarter.
-
Convertible Notes with 35% Discount
Outstanding Alpha Promissory Notes of $450,000 convert at a 35% discount to market price upon business combination, creating potential dilution.
Analysis · DMII · Real Estate & Construction
The 10-Q reveals a working capital deficit of $426,751 and reiterates substantial doubt about the company's ability to continue as a going concern. Management also discloses a material weakness in internal controls and that the sponsor cannot repay $782,113 owed to the company. New convertible notes totaling $450,000 carry a 35% conversion discount, creating significant potential dilution for existing holders if a business combination occurs.
At the time of this filing, DMII was trading at $10.13 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $645.3M. The 52-week trading range was $9.86 to $10.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.